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Aim To determine the safety and efﬁcacy of nebivolol in elderly heart failure (HF) patients with renal dysfunction.
Methods
and results
SENIORS recruited patients aged 70 years or older with symptomatic HF, irrespective of ejection fraction, and ran-
domized them to nebivolol or placebo. Patients (n ¼ 2112) were divided by tertile of estimated glomerular ﬁltration
rate (eGFR). Mean age of patients was 76.1 years, 35% of patients had an ejection fraction of .35%, and 37% were
women resulting in a unique cohort, far more representative of clinical practice than previous trials. eGFR was
strongly associated with outcomes and nebivolol was similarly efﬁcacious across eGFR tertiles. The primary
outcome rate (all-cause mortality or cardiovascular hospital admission) and adjusted hazard ratio for nebivolol use
in those with low eGFR was 40% and 0.84 (95% CI 0.67–1.07), 31% and 0.79 (0.60–1.04) in the middle tertile,
and 29% and 0.86 (0.65–1.14) in the highest eGFR tertile. There was no interaction noted between renal function
and the treatment effect (P ¼ 0.442). Nebivolol use in patients with moderate renal impairment (eGFR ,60) was not
associated with major safety concerns, apart from higher rates of drug-discontinuation due to bradycardia.
Conclusion Nebivolol is safe and has a similar effect in elderly HF patients with mild or moderate renal impairment.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Decreased renal function has consistently been found to be an
independent risk factor for cardiovascular (CV) disease outcomes
and all-cause mortality in a large spectrum of patients including
those with left ventricular systolic dysfunction and heart failure
(HF).
1–3 However, most studies in HF have been conducted in
patients with a mean age of 60–65 years and markedly reduced
left-ventricular ejection fraction (LVEF), a pattern very dissimilar
to the ‘average’ patient with HF.
4 Data in patients aged more
than 70 years or with preserved systolic function are scarce.
Altered renal function is also a restriction to the initiation and titra-
tion of HF therapy
5 that may limit treatment effectiveness
especially in the elderly. Beta-blockers are now considered a
routine treatment in patients with symptomatic HF and have
been shown to improve ventricular function and reduce morbidity
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6,7 However, no study has previously assessed the
interaction between beta-blocker response and renal function in
elderly HF patients.
SENIORS (Study of the Effects of Nebivolol Intervention on
Outcomes and Rehospitalization in Seniors with Heart Failure)
was undertaken to determine the effect of nebivolol on mortality
and morbidity in elderly patients with HF, regardless of ejection
fraction, when compared with placebo. The primary outcome
(composite of all cause mortality or CV hospital admission) was
signiﬁcantly reduced in those taking nebivolol [31.1% compared
with 35.3% on placebo; hazard ratio (HR) 0.86, 95% CI 0.74–
0.99; P ¼ 0.039].
8 In addition, no signiﬁcant inﬂuence of age or
gender was observed and we have recently demonstrated that
the efﬁcacy of nebivolol was not dependent on baseline LVEF.
9
The aim of this analysis was to conﬁrm whether nebivolol was
effective in participants of SENIORS with mild or moderate renal
impairment and determine whether the safety proﬁle was different
in these patients.
Methods
The rationale and details of SENIORS have been described previously.
8
Eligible patients were women and men aged 70 years or older who had
symptomatic HF (New York Heart Association class II–IV) of at least
4 weeks duration. LVEF was recorded in all participants but was not a
speciﬁc entry criterion. To ensure that HF patients were recruited,
inclusion criteria speciﬁed an LVEF of ,35% within 6 months or
prior hospitalization for decompensated HF in the previous year
whatever the level of LVEF. Participants were randomized on a 1:1
basis to an up-titrating dose (target 10 mg) of nebivolol or placebo.
Exclusion criteria included serum creatinine  250 mmol/L as well as
recent change in drug therapy and contraindication/intolerance to
beta-blockers.
The primary outcome was the composite of all-cause mortality or
CV hospital admission (time to ﬁrst event) and secondary outcomes
included all-cause mortality, all-cause hospital admissions, CV hospital
admissions, and CV mortality. For the 2112 participants in this analysis,
the mean follow-up period was 20.89 months with a standard devi-
ation (SD) of 9.2 months.
Renal function
Plasma creatinine was measured in SENIORS participants at baseline
and at the ﬁnal follow-up visit. Sixteen participants with missing base-
line values were not included in this analysis. Renal function was esti-
mated using the abbreviated Modiﬁcation of Diet in Renal Disease
(MDRD) formula. The MDRD four-component equation incorporates
age, race, gender, and serum creatinine level and describes estimated
glomerular ﬁltration rate (eGFR) in millilitres per minute standardized
to a body surface area of 1.73 m
2:
eGFR ¼ 32788  ½ creatinine mmol/L 
 1:154  ½ age 
 0:203
 ½ 0:742 if female  ½ 1:212 if Afro-Caribbean 
Estimated GFR was divided into tertiles to maximize the power of
the statistical analysis. Ranges for the low, middle, and high eGFR ter-
tiles are ,55.5, 55.5–72.8, and .72.8 mL/min respectively. Thus, the
low eGFR tertile broadly corresponds to Stage 3 kidney disease
(moderately reduced renal function), as categorized by the National
Kidney Foundation.
10
Statistics
Values are reported as mean with SD or numbers (percentage) as
appropriate. When assessing the difference between treatment and
placebo, continuous variables were compared using two-tailed t-tests
and categorical variables were assessed using a x
2 test. For compari-
sons across tertiles of eGFR, continuous variables were analysed
using one-way ANOVA and categorical variables using a x
2 test. Multi-
variate analysis was performed using Cox regression methods. Vari-
ables for the adjusted multivariate analysis were pre-speciﬁed:
smoking, gender, ethnicity, age, heart rate, systolic blood pressure,
diastolic blood pressure, New York Heart Association (NYHA)
class, medical history (diabetes, prior angina, prior stroke, or prior
myocardial infarction), and LVEF. To examine extra covariates felt to
confound or effect-modify the association of beta-blocker treatment
and HF outcomes, we carried out additional post hoc adjustments for
medication usage, nebivolol dose, and haemoglobin. A P-value of
,0.05 was considered statistically signiﬁcant. Analyses were per-
formed on Stata (version 10.1, StataCorp LP).
Results
Baseline characteristics according
to renal function
Baseline data for the SENIORS cohort have previously been
reported.
8 In brief, SENIORS participants were much older than
other beta-blocker trials (mean age 76.1, SD 4.6) with a range of
LVEF (mean 36.0%, SD 12.3%) that better represents the clinical
population of HF patients. Mean eGFR for the entire cohort was
65.0 (SD 20.4) mL/min. Only 9.9% of patients had normal renal
function as deﬁned by eGFR  90 mL/min. A total of 48.1% of
patients had mild renal impairment (eGFR 60–89) and 38.9% mod-
erate impairment (eGFR 30–59). Despite exclusion based on crea-
tinine level, 3.1% of patients had severely reduced kidney function
(eGFR ,30). Figure 1 shows the distribution of eGFR according to
age and LVEF.
Table 1 presents demographic characteristics by tertile of eGFR.
Participants with impaired renal function were more likely to be
older, female, with lower LVEF and lower blood pressure (BP).
Rates of prior myocardial infarction, coronary revascularization,
and diabetes were also higher in those with reduced eGFR.
Medication usage (data not shown) was also signiﬁcantly different
according to eGFR tertile; participants with poorer renal function
were prescribed more diuretics and angiotensin receptor blockers
but less angiotensin converting enzyme inhibitors. The use of
aldosterone antagonists, anti-arrhythmics, and lipid-lowering
agents was also more common in those with impaired kidney
function.
Within-group characteristics were similar between patients allo-
cated to nebivolol or placebo (Table 1) despite randomization not
stratifying by renal function. The middle eGFR tertile included non-
signiﬁcantly more women allocated to nebivolol, with a small but
signiﬁcantly lower systolic BP (139.0 vs. 142.1 mmHg in the
placebo arm; P ¼ 0.049). However, all other variables were com-
parable between treatment groups.
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Adverse outcomes were signiﬁcantly more common in SENIORS
participants with reduced renal function, conﬁrming higher rates
of mortality and HF morbidity in patients with moderate or
severe renal impairment (Figure 2). The primary outcome (compo-
site of all-cause mortality or CV hospital admission) occurred in
28.7, 31.0, and 40.1% of those in the high, middle, and low eGFR
tertiles, respectively (P-value for trend ,0.001). For all-cause mor-
tality, the rates were 11.9, 15.6, and 23.2% (P , 0.001). The risk of
death for patients in the lowest eGFR tertile was over twice that
seen for patients in the highest eGFR tertile (HR 2.09, 95% CI
1.61–2.72; P , 0.001).
Efﬁcacy of nebivolol in patients
with impaired renal function
Table 2 presents the primary and main secondary outcomes by ter-
tiles of eGFR. There was no interaction between renal function and
the effect of nebivolol on outcome (P ¼ 0.442). Similarly for the
secondary outcomes, including CV hospitalization and mortality,
renal impairment had no effect on the efﬁcacy of nebivolol treat-
ment. Table 3 describes crude hazard ratios for the primary
outcome by eGFR tertile and those adjusted for smoking,
gender, ethnicity, age, heart rate, systolic blood pressure, diastolic
blood pressure, NYHA class, medical history, and LVEF. Figure 3
depicts forest plots for these analyses. The degree of renal
Figure 1 Estimated glomerular ﬁltration rate by age and ventricular function. Renal function divided by age (top, 1-year intervals) and left-
ventricular ejection fraction (bottom, 5% intervals), with error bar indicating upper 95% conﬁdence interval.
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Table 1 Demographic characteristics by estimated glomerular ﬁltration rate tertile
Variable Low eGFR tertile (<55.5 mL/min/
1.73 m
2)
Middle eGFR tertile (55.5–72.8 mL/
min/1.73 m
2)
High eGFR tertile (>72.8 mL/min/
1.73 m
2)
P-value across tertiles
NEB PLC P-value NEB PLC P-value NEB PLC P-value
n 348 356 346 358 366 338
eGFR, mL/min (SD) 43.4 (9.1) 43.5 (8.8) 0.899 64.2 (5.1) 64.3 (5.1) 0.779 87.1 (13.3) 87.3 (13.8) 0.791 ,0.001
Creatinine, mmol/L (SD) 137.8 (37.0) 137.8 (36.1) 0.995 94.6 (13.2) 96.2 (13.0) 0.109 75.1 (11.8) 75.3 (12.3) 0.853 ,0.001
Age, years (SD) 77.3 (5.0) 77.4 (5.1) 0.983 76.1 (4.7) 75.8 (4.3) 0.501 75.0 (4.2) 75.1 (3.8) 0.739 ,0.001
Female,% 41.7 39.9 0.631 41.0 34.1 0.056 32.8 31.7 0.749 0.004
Previous MI,% 44.3 48.6 0.248 48.3 46.7 0.667 39.1 35.5 0.328 ,0.001
Diabetes, % 29.9 28.7 0.719 25.7 24.9 0.792 24.9 22.2 0.404 0.045
Current smoker,% 4.9 5.9 0.552 3.8 4.8 0.515 6.0 5.3 0.688 0.438
Hyperlipidaemia
a,% 44.8 48.9 0.282 47.1 49.4 0.536 45.9 38.8 0.055 0.073
LVEF, mean% (SD) 34.0 (12.0) 34.4 (12.2) 0.678 35.7 (12.1) 36.2 (11.9) 0.645 38.1 (12.9) 37.4 (11.9) 0.448 ,0.001
NYHA class I/II,% 55.5 53.7 0.630 61.0 60.3 0.860 61.8 62.4 0.853 0.009
NYHA class III/IV,% 44.5 46.3 0.630 39.0 39.7 0.860 38.2 37.6 0.853 0.009
Systolic BP, mmHg (SD) 134.3 (20.5) 133.6 (20.2) 0.636 139.0 (19.1) 142.1 (21.8) 0.049 142 (19.9) 143.2 (19.8) 0.485 ,0.001
Diastolic BP, mmHg (SD) 78.1 (11.1) 78.0 (10.9) 0.896 81.3 (10.7) 81.3 (11.5) 0.972 82.1 (10.1) 82.7 (10.9) 0.445 ,0.001
Body mass index, kg/m
2 (SD) 26.6 (4.6) 26.6 (4.2) 0.777 27.0 (3.9) 26.9 (3.9) 0.808 26.8 (4.0) 26.6 (3.7) 0.544 0.241
NEB, nebivolol; PLC, placebo; MI, myocardial infarction; BP, blood pressure.
aDeﬁned as known history of hyperlipidaemia or treatment.
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5impairment, as divided by eGFR tertiles, did not inﬂuence the effect
of nebivolol on outcomes. Further adjustment for medication
usage had no impact on hazard ratios (data not shown).
Safety of nebivolol in patients with
impaired renal function
Nebivolol was very well tolerated in the SENIORS cohort with
hypotension being the only signiﬁcant adverse outcome causing
excess drug discontinuation when compared with placebo (4 vs.
0 patients). As the total number of adverse events was very
small, Table 4 lists adverse events and achieved dosage according
to an eGFR cut-off of 60 mL/min rather than tertiles of eGFR. In
participants randomized to nebivolol, those with moderate renal
impairment or worse had a comparable safety proﬁle to partici-
pants with normal or mild renal impairment, apart from a margin-
ally signiﬁcant increase in bradycardia [10 out of 440 patients
(2.3%) vs. 5 out of 620 patients (0.8%); P ¼ 0.046]. The achieved
dose of nebivolol was lower in participants with reduced eGFR
but these patients still achieved a clinically appropriate dose of
7.3 (SD 3.7) vs. 8.0 (SD 3.3) mg in those with eGFR . 60 (P ¼
0.004).
Patients in both the treatment and placebo arms experienced a
decline in renal function over the course of the 2 year follow-up
period. The mean reduction in eGFR was 9.1 (SD 15.4) mL/min
in the nebivolol group and 8.7 (SD 14.7) mL/min in the placebo
arm (within-group P-value for both, ,0.001). However, this
reduction was not statistically different between the treatment
groups (P ¼ 0.549).
Discussion
In this paper, post hoc analysis of the SENIORS data is presented
with respect to baseline renal function. SENIORS was not
powered to detect reductions in the primary outcome for the
renal sub-groups and hence none of the eGFR tertiles reach stat-
istical signiﬁcance. However, the interaction analysis between renal
function and the effect of nebivolol was not signiﬁcant, which
strongly suggests that the efﬁcacy of nebivolol is not reduced in
elderly HF patients with mild or moderate renal impairment. In
addition, nebivolol was safe for use in those with renal dysfunction,
albeit with a marginal increase in bradycardia-related treatment
discontinuation.
Guidelines for the treatment of HF now include beta-blocker
therapy for all symptomatic patients.
6,7 However, uptake of beta-
blockers in the clinical setting remains sub-optimal and may
reﬂect a reluctance to prescribe these and other evidence-based
medications to a patient group with high levels of co-morbid con-
ditions and advanced age.
11 Furthermore, there is a general
concern that the participants of existing randomized controlled
trials do not reﬂect the actual population of HF patients. In particu-
lar, trials have often excluded HF patients with preserved systolic
function and renal insufﬁciency.
12 The SENIORS trial enrolled
patients with a wide range of LVEF (one-third with ejection frac-
tion .35%) and 50% were aged  75 years. Even in this cohort,
nebivolol signiﬁcantly reduced the primary composite outcome
of all-cause mortality or CV hospital admission. As demonstrated
by the Hypertension in the Very Elderly Trial (HYVET), adequate
treatment even in patients of advanced age can result in clinically
signiﬁcant improvements in CV outcomes.
13
Figure 2 Survival curves for all participants by estimated glomerular ﬁltration rate tertile according to primary outcome (A) and all-cause
mortality (B). Black, solid: low estimated glomerular ﬁltration rate tertile (,55.5 mL/min); Grey, solid: middle estimated glomerular ﬁltration
rate tertile (55.5–72.8 mL/min); Black, dashed: high estimated glomerular ﬁltration rate tertile (.72.8 mL/min). Primary outcome was all-cause
mortality or cardiovascular hospitalization. Using the high glomerular ﬁltration rate tertile as the reference group, there was no signiﬁcant differ-
ence noted for the middle tertile (P ¼ 0.486) but a highly signiﬁcant increase in the primary outcome for those in the low estimated glomerular
ﬁltration rate tertile (P , 0.001). Similarly for all-cause mortality, the respective P-values are 0.06 and ,0.001.
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Table 2 Primary and main secondary outcomes by tertile of estimated glomerular ﬁltration rate
Outcome Low eGFR tertile (<55.5 mL/min/
1.73 m
2)
Middle eGFR tertile (55.5–72.8 mL/min/
1.73 m
2)
High eGFR tertile (>72.8 mL/min/
1.73 m
2)
Interaction
P-value
a
NEB, n (%) PLC, n (%) HR (95% CI) NEB, n (%) PLC, n (%) HR (95% CI) NEB, n (%) PLC, n (%) HR (95% CI)
Primary outcome (all- cause mortality or CV
hospitalization)
129 (37.1) 153 (43.0) 0.81 (0.64, 1.03) 98 (28.3) 120 (33.5) 0.83 (0.63, 1.08) 103 (28.1) 99 (29.3) 0.93 (0.70, 1.22) 0.442
All-cause mortality 71 (20.4) 92 (25.8) 0.76 (0.56, 1.03) 57 (16.5) 53 (14.8) 1.14 (0.78, 1.66) 40 (10.9) 44 (13.0) 0.82 (0.53, 1.25) 0.521
CV hospitalization 100 (28.7) 104 (29.2) 0.93 (0.70, 1.22) 72 (20.8) 97 (27.1) 0.74 (0.55, 1.00) 82 (22.4) 73 (21.6) 1.04 (0.76, 1.42) 0.637
CV mortality 49 (14.1) 67 (18.8) 0.72 (0.50, 1.04) 46 (13.3) 43 (12.0) 1.11 (0.74, 1.69) 28 (7.7) 32 (9.5) 0.81 (0.49, 1.35) 0.494
Hazard ratios (HR) represent the effect of nebivolol (NEB) when compared with placebo (PLC). CV, cardiovascular.
aInteraction for renal function and effects of nebivolol.
................................. .............................................. ..............................................
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Table 3 Crude and adjusted analysis for the primary outcome according to estimated glomerular ﬁltration rate tertile
Estimated glomerular ﬁltration rate Number of patients Primary outcome Crude Adjusted
Events Percentage HR 95% CI P-value HR 95% CI P-value
Low eGFR tertile 704 282 40 0.81 (0.64, 1.03) 0.087 0.84 (0.67, 1.07) 0.158
Middle eGFR tertile 704 218 31 0.83 (0.63, 1.08) 0.164 0.79 (0.60, 1.04) 0.092
High eGFR tertile 704 202 29 0.93 (0.70, 1.22) 0.597 0.86 (0.65, 1.14) 0.303
Continuous 2112 702 33 0.85 (0.73, 0.99) 0.032 0.85 (0.73, 0.98) 0.030
Hazard ratios (HR) represent the effect of nebivolol when compared with placebo. The adjusted analysis includes smoking, gender, ethnicity, age, heart rate, systolic blood pressure, diastolic blood pressure, NYHA class, medical history
(diabetes, prior angina, prior stroke, or prior myocardial infarction) and left-ventricular ejection fraction.
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7Renal impairment is a common ﬁnding in patients with HF and is
independently associated with an increased risk of death.
14,15 Our
data support this ﬁnding in an elderly HF cohort. The link between
HF and kidney disease has received considerable attention and
likely reﬂects a number of superimposed factors.
5 For example,
renal impairment may indicate a worsened state of HF or paradoxi-
cally cause progression of ventricular dysfunction.
16 HF patients
with renal impairment are also less likely to be prescribed effective
treatment.
17
Use of beta-blockers in HF patients with kidney disease is known
to improve outcomes.
17–19 Mechanistically, this improvement may
be linked to reduction in activity of the renin–angiotensin system,
improvement in renal blood ﬂow, and improved natriuresis in
response to volume loading.
20 However, only a few studies have
compared the effects of beta-blockade in HF patients with and
without renal dysfunction. The Cooperative Cardiovascular
Project was a non-randomized observational study using propen-
sity score matching in patients over 65 years who survived a
myocardial infarction. In the 2613 participants on beta-blockers,
a greater beneﬁt was noted for patients with serum creatinine
levels of 2.0 mg/dL [176.8 mmol/L] or greater (P ¼ 0.02).
21 Sub-
group analysis of CIBIS (Cardiac Insufﬁciency Bisoprolol) II, a ran-
domized controlled trial of bisoprolol in symptomatic patients with
ejection fraction  35% and mean age 61 years, showed similar
beneﬁt for beta-blocker treatment in those with creatinine clear-
ance ,60 and  60 mL/min.
22 Finally, a sub-analysis of
MERIT-HF (Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure) is considered in which 3991 participants
with LVEF  40% and mean age of 64 were randomized to
controlled-release metoprolol or placebo.
23 Renal function,
divided into MDRD eGFR groups, was a strong and independent
predictor of outcomes. The beneﬁt of beta-blockade was noted
in all eGFR groups, with no signiﬁcant interaction for renal function
and total mortality (interaction P-value ¼ 0.095). Our analysis con-
ﬁrms the latter two results and for the ﬁrst time extends these
conclusions to an HF population more typical of clinical practice,
that is older and with a wide range of LVEF. The number needed
to treat (NNT) with nebivolol for the primary outcome in the
whole cohort was 24. Patients in the lowest tertile of eGFR had
a similar NNT of 17, although we were underpowered to detect
differences between the eGFR tertiles. However, as CV outcomes
were more common in those with impaired renal function, the
absolute clinical beneﬁt may actually be greater in these patients.
The good renal tolerance of nebivolol even in this group of
patients may be explained by its unique ability to vasodilate renal
arteries via endothelial-dependent nitric oxide,
24 independently
of effects on adreno-receptors.
25 Nebivolol has a higher degree
of beta-1 selectivity than any other beta-blocker, explaining the
minimal effects noted on the airways of asthmatic patients or
insulin sensitivity in those with diabetes.
26 Metabolism and elimin-
ation of nebivolol is almost entirely through hepatic cytochrome
P450 enzymes, although the minimal amount of drug excreted
unchanged in the urine can be important in patients with severe
renal impairment.
26 This may explain the higher rate of bradycardia
seen in those with low eGFR in our study.
The effect of beta-blockers on the natural history of renal func-
tion in patients with HF remains largely unknown. Beta-blockade
has the potential to improve renal function, presumably by
Figure 3 Forest plot for primary outcome by estimated glo-
merular ﬁltration rate tertile. Adjusted analysis includes
smoking, gender, ethnicity, age, heart rate, systolic blood
pressure, diastolic blood pressure, NYHA class, medical history
(diabetes, prior angina, prior stroke or prior myocardial infarc-
tion), and left-ventricular ejection fraction.
............................................. ............................................. ........................................
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Table 4 Safety data by estimated glomerular ﬁltration rate and treatment group
Event Nebivolol Placebo Whole group
eGFR < 60 eGFR   60 P-value eGFR < 60 eGFR   60 P-value Nebivolol Placebo P-value
Number 440 620 446 606 1060 1052
Final dose at end of titration 7.3+3.7 8.0+3.3 0.004 8.2+3.3 8.7+2.9 0.003 7.7+3.5 8.5+3.1 ,0.001
Hypotension
a 2 (0.5) 2 (0.3) 0.730 0 (0) 0 (0) – 4 (0.4) 0 (0) 0.046
Renal failure
a 0 (0) 1 (0.2) 0.399 0 (0) 1 (0.2) 0.391 1 (0.1) 1 (0.1) 0.996
Bradycardia
a 10 (2.3) 5 (0.8) 0.046 3 (0.7) 5 (0.8) 0.391 15 (1.4) 8 (0.8) 0.147
HF
a 12 (2.7) 9 (1.5) 0.142 9 (2.0) 5 (0.8) 0.095 21 (2.0) 14 (1.3) 0.242
Any event
a 23 (5.2) 15 (2.4) 0.015 11 (2.5) 10 (1.7) 0.350 38 (3.6) 21 (2.0) 0.027
Safety data in the SENIORS trial according to renal function and treatment arm.
aLeading to drug discontinuation. Nebivolol dose described as mean dose (mg)+SD; other variables are total number (percentage).
A. Cohen-Solal et al. 878improvement in cardiac output and a concomitant increase in renal
perfusion,
27 supplementing the direct glomerular effects of beta-1
receptor antagonism. In a small double-blind crossover study, nebi-
volol preserved renal blood ﬂow when compared with atenolol,
the latter causing a signiﬁcant drop in GFR.
28 In the setting of
reduced renal perfusion in HF, venous congestion is also a deter-
minant of GFR
29 and another target for agents that block sympath-
etic activation. Our data, the ﬁrst involving an elderly HF cohort,
found no improvement over 2 years in renal function, but did
conﬁrm that nebivolol was as safe as placebo with regards to
longer term kidney function, even in those patients with moderate
impairment at baseline. However, these issues can only be fully
addressed in a prospective controlled trial or an individual
patient meta-analysis of all beta-blocker trials, which is currently
being explored.
30
Analysis of the dose of nebivolol achieved has identiﬁed that
lower doses may have less impact on outcomes and those intoler-
ant of beta-blockers have a signiﬁcantly higher risk of death or CV
admission when compared with placebo (adjusted hazard ratio
1.95, 95% CI 1.38–2.75).
31 Anaemia is also a powerful independent
predictor of HF outcomes
32 and is associated with impaired renal
function through inadequate erythropoietin production.
33 Previous
studies have not reported the association of baseline haemoglobin
with renal function in HF and the subsequent effects on beta-
blocker efﬁcacy. To account for these potential modiﬁers on the
effect of nebivolol in participants with reduced eGFR, we further
adjusted our multivariate analysis for dose and baseline haemo-
globin. In the low eGFR tertile (,55 mL/min), the hazard ratio
for the primary outcome was unchanged when compared with
the pre-speciﬁed analysis (0.87, 95% CI 0.68–1.11; P ¼ 0.250).
Limitations of study
This analysis is based on subgroups from the SENIORS cohort and
is thus liable to the usual limitations of such methods. In particular,
we were statistically underpowered to detect signiﬁcant improve-
ment in the primary outcome for the eGFR subgroups. Neverthe-
less, each tertile had a trend towards beneﬁt, and interaction
P-values were consistently non-signiﬁcant across the secondary
outcomes. Another limitation was the exclusion of patients with
a creatinine level of .250 mmol/L. This level was a pre-determined
exclusion criterion based on licensing restrictions for nebivolol in
some of the countries participating in SENIORS recruitment. As
such the conclusions for this analysis cannot be extended to
patients with severe renal impairment. We chose to describe
renal function in terms of the MDRD formula, which has been vali-
dated in HF patients.
34,35 Although eGFR by this technique is
higher than with other methods,
36 supplementary analysis of the
SENIORS data based on serum creatinine and Cockroft-Gault
clearance resulted in identical conclusions.
Conclusions
In elderly HF patients with a wide range of ejection fraction, mild
and moderate impairment of renal function did not interact with
the effect of nebivolol on clinical outcomes. Furthermore, nebivo-
lol was well tolerated in participants of the SENIORS trial with
moderate renal impairment. Thus, mild to moderate renal
dysfunction, even in the elderly, should not present a limitation
to the use of nebivolol in HF patients.
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